Editorial Board
Editor in Chief
​Dr Paolo Sbraccia


Paolo Sbraccia, M.D, Ph.D. is Full Professor of Internal Medicine in the Department of Systems Medicine of the University of Rome "Tor Vergata", Chief of the Internal Medicine Unit and Obesity Center (EASO accredited Collaborating Centre for Obesity Management) at the University Hospital Policlinico Tor Vergata, Director of the Specialization School in Internal Medicine, and Chairman of the Undergraduate Course in Dietetics.
Prof. Sbraccia is also currently serving as President of the Italian Federation of Endocrinology, Diabetology, Andrology, Metabolism and Obesity and as Vice President of the Italian Barometer Diabetes Observatory. In addition, he is Past President of the Italian Society of Obesity.
He was also member of the “Scientific Advisory Group for Diabetes and Endocrinology” of the European Medicine Agency (EMA, 2008-2015). In 2011, on behalf of SIO, he coordinated the Steering Committee for the Italian Guidelines for the Management of Obesity, and in 2016 he was Editor of the book “Clinical Management of Overweight and Obesity, Recommendations of the Italian Society of Obesity (SIO)”.
Prof. Sbraccia is also a member of the editorial boards and reviewer panels of various scientific journals; in particular, he is associate Editor of “Eating and weight disorders” and “Internal and Emergency Medicine”.
Co-Editor in Chief
Dr Marwan El Ghoch, MD
Marwan El Ghoch is ​Professor in Clinical Nutrition – Head of the Department of Nutrition & Dietetics at the Faculty of Health Sciences - Beirut Arab University, Lebanon. He earned the degree in Medicine and Surgery from the University of Bologna, Italy, followed by 4 years postgraduate studies in Clinical Nutrition from the University of Modena and Reggio Emilia, Italy. He is considered an expert in obesity and eating disorders treatments, and gained an international leadership in the study of the two-component model of body composition (DXA scan). Author of more than 70 papers published in high-ranking peer-review journals in the field of Medicine, Nutrition and Dietetics.
Associate Editor
Alessandra Valerio, MD
Associate Professor of Pharmacology at the Department of Molecular and Translational Medicine (DMMT), School of Medicine, University of Brescia – Italy. Prof. Valerio is also a member in the Italian Society of Pharmacology (SIF), Italian Society of Neuroscience (SINS), Italian Society of Obesity (SIO) and European Association for the Study of Obesity (EASO). She is responsible for the Nutrition & Metabolism platform of DMMT, Brescia University. She is involved in preclinical and translational studies in the field of healthy living and ageing. Her main area of research is focusing on pharmacological, nutraceutical and lifestyle approaches able to boost mitochondrial biogenesis and function for the prevention and management of neurodegenerative and other age-related chronic diseases. She is author of Author of more than 60 articles in peer-reviewed international Journals and contributor of more than 150 communications to national or international scientific meetings. Sum of the times cited: 4062; h-index: 31 (Scopus© Elsevier BV, June 24, 2019).
Advisory Board Member
​Mitchell Levine,

​Dr. Mitchell Levine received his medical degree from the University of Calgary, which was followed by postgraduate medical training in Internal Medicine and in Clinical Pharmacology at the University of Toronto. He received an MSc in Clinical Epidemiology from McMaster University.

Dr. Levine is a Professor at McMaster University in the Department of Health Research Methods, Evidence and Impact and in the Department of Medicine, Division of Clinical Pharmacology. He is the Director for the Program for Assessment of Technology in Health (P.A.T.H) and the Director for the Centre for Evaluation of Medicines (both affiliated with St. Joseph’s Healthcare Hamilton and McMaster University). Dr. Levine is a practicing consultant physician in the fields of Internal Medicine and Clinical Pharmacology at St. Joseph's Healthcare Hamilton.

Dr. Levine is the Vice-Chair of the Patented Medicine Prices Review Board of Canada. He also serves as an advisor to governments on issues relating to drug safety, efficacy and pharmaco-economics. He is a consultant to the Drug Benefits Program of the Ontario Ministry of Health and Long Term Care and to Health Canada.

His academic activities include assessing prescription drug use in the community and developing methods to obtain maximum value from drug therapy resources. He is the Editor for both the Canadian Journal of General Internal Medicine and the Journal of Population Therapeutics and Clinical Pharmacology, and is an Associate Editor for ACP Journal Club and Evidence-Based Medicine.
Editorial Board Member
Enzo Nisoli MD, PhD
Full Professor of Pharmacology at the Department of Medical Biotechnology and Translational Medicine (BIOMETRA), School of Medicine, University of Milan – Italy. He is the Past-President of the Italian Obesity Society (SIO 2014-2016) and currently covers the role of CME Referee of the Italian Ministry of Health, section of Pharmacology and Toxicology. Prof. Nisoli is also a member in the Italian Society of Pharmacology (SIF), Italian Society of Obesity (SIO) and European Association for the Study of Obesity (EASO). His main area of research is focused on pharmacology, obesity and disorders of metabolism, nutrition science, amino acid metabolism, aging and health span extension, mitochondrial bioenergetics and supplements. He is an author of 130 articles in peer-reviewed international Journals with a sum of the times cited: 6014 citations, h index 37, ISI Web of Science®; 6571 citations, h index 38, Scopus© Elsevier BV; and 9186 citations, h index 42, Google Scholar.
Lisa Dolovich, PhD

​Dr. Lisa Dolovich is the Ontario College of Pharmacists Professor in Pharmacy Practice at the Leslie Dan Faculty of Pharmacy at the University of Toronto and a Professor in the Department of Family Medicine (and cross appointed to the Departments of Clinical Epidemiology and Biostatistics and Medicine) at McMaster University. She is also a Scientist with the Centre for Evaluation of Medicines at St. Joseph’s Healthcare, Hamilton, an Associate Professor at the Leslie Dan Faculty of Pharmacy, University of Toronto and an Adjunct Associate Clinical Professor in the School of Pharmacy University of Waterloo.  

Dr. Dolovich is an expert in the implementation and evaluation of complex interventions in community based primary health care including pharmacy practice, implementation science methods, interdisciplinary healthcare team integration, and research on medication prescribing and use. 
​Savithiri Ratnapalan, MB, BS, MEd, MRCP, FRCPC, FAAP

​Savithiri Ratnapalan is an Associate Professor in the Department of Paediatrics and the Dalla Lana School of Public Health at t University of Toronto and a Clinician-Educator in the Divisions of Emergency Medicine, Clinical Pharmacology, and Toxicology at the Hospital for Sick Children in Toronto, Canada. 
Sarah Burgess, RPh, ACPR, PharmD 

Sarah Burgess is a clinical pharmacist currently integrated into a collaborative primary care clinic in rural Nova Scotia.   In addition to her clinical practice, Ms. Burgess lectures for the undergraduate pharmacy program at the College of Pharmacy, Dalhousie University and has been involved in co-coordinating and teaching the Critical Appraisal Series course which focuses on critically evaluating the medical literature and applying evidence to clinical practice and decision making.  
Ms. Burgess is also affiliated with the Drug Assessment Working Group for the Therapeutics Initiative, University of British Columbia which analyzes the scientific evidence on the effectiveness and safety of drug therapies used in Canada.  Her research interests include pharmacy practice, optimal medication use and deprescribing.   

Ms. Burgess graduated from the College of Pharmacy at Dalhousie University (Halifax, NS) in 2010 and then completed a hospital pharmacy residency in London, Ontario.  From 2011 to 2013, Ms. Burgess was a clinical pharmacist on the Internal Medicine service at London Health Sciences Centre.  In 2015, Ms. Burgess completed a 2-year post-graduate Doctor of Pharmacy at the University of British Columbia.
​Folefac Aminkeng, BMLS, MSc, PhD
Dr. Folefac Aminkeng  is an Assistant Principal Investigator and the Associate Head of the Pharmacogenomics and Personalized Medicine Program at the Agency for Science Technology and Research (A*STAR) in Singapore. His central research interests are on the "Pharrmacogenomics of Adverse Drug Reactions in Oncology", with a particular focus on Cardiotoxicity, Ototoxicity, Nephrotoxicity and Neurotoxicity. He is interested in bio-marker discovery, validation, translation and guidelines development, as well the implementation of pharmacogenomic testing to provide real time decision support to improve the safety of cancer treatments. Folefac obtained his master's degree and PhD in Medical Sciences from the Vrije Universiteit Brussel in Belgium and did his postdoctoral training on Pharmacogenomics and Precision medicine at the Centre for Molecular Medicine and Therapeutics of the British Columbia Children Hospital Research Institute  and the Department of Medical Genetics of the University of British Columbia. He has made significant contributions to the field of pharmacogenomics, including the identification of a gene that is involved in cardiomyopathy and congestive heart failure after cancer treatment (Aminkeng F et al, Nature Genetics. 2015 Sep; 47(9):1079-84.). He is the recipient of a number of fellowships including the Canadian Institutes of Health Research, Michael Smith Foundation for Health Research and the British Columbia Children Hospital Research Institute Bertram Hoffmeister Postdoctoral Fellowships. He has also been recognized for a distinguish academic and scientific career through a number of career awards including the Canadian Society of Pharmacology and Therapeutics Boehringer Ingelheim Postdoctoral Award in Pharmacology, the British Columbia Children Hospital Research Institute award for outstanding achievement by a postdoctoral fellow, the Golden Helix Top Prize and the Canadian Society of Pharmacology and Therapeutics Publication Award. He currently serves on the Canadian Society of Pharmacology and Therapeutics Scientific Program Committee and is a member of several academic societies including the American Association of Pharmaceutical Scientists, British Pharmacological Society, European Society of Pharmacogenomics and Personalized Therapy, Canadian Association for Population Therapeutics, American Society of Human Genetics and Canadian Society for Pharmaceutical Sciences.
​Colleen Maxwell, PhD

Dr. Colleen Maxwell is a Professor with the Schools of Pharmacy and Public Health & Health Systems, University of Waterloo, an Adjunct Scientist with the Institute for Clinical Evaluative Sciences (ICES), and an Adjunct Professor with Community Health Sciences, University of Calgary. She is a senior health services researcher with expertise in aging, frailty, continuing care and pharmacoepidemiology. Her research interests include the quality of care and pharmacotherapy of older vulnerable populations across the care continuum – particularly those with dementia, depression and related disorders. A particular focus within these areas is the investigation of different approaches to screen for (and grade) levels of frailty among older adults with the goal of using this information for improving geriatric pharmacotherapy and outcomes.

​Dr. Maxwell is a past Board Member of the International Society for Pharmacoepidemiology, Canadian Association for Population Therapeutics and a current Board Member of the Canadian Society for Epidemiology and Biostatistics and the PROPEL Centre for Population Health Impact (University of Waterloo).
Guy Chouinard, MD, M.Sc. (Pharmacol) FRCP(C), FAPA

Dr. Guy Chouinard was a Professor of Psychiatry and Medicine at McGill University and Professor of Psychiatry at the University of Montreal. He was an Invited Professor at the Faculties of Biology and Medicine at the University of Lausanne in Switzerland, and University of Paris-Sud XI in France. He is Director Emeritus of the Psychotic Disorders External Services at the McGill University Health Center at McGill University, Founding Director and Director Emeritus of the Royal College Accredited Program in Clinical Pharmacology and Toxicology at McGill University, Founding Director and Director Emeritus of the Clinical Psychopharmacology Unit, McGill University Health Center at McGill University. 

Dr. Chouinard is a Founding Member of the Specialty of Clinical Pharmacology, Royal College of Physicians and Surgeons of Canada, and a Founding Member of the Canadian College of Neuropsychopharmacology. His psychopharmacological research has significantly contributed to the progress of pharmacological treatments of schizophrenia, bipolar disorder, major depression and anxiety disorders.  He conducted pioneering and innovative studies of benzodiazepine and non-benzodiazepine antianxiety/hypnotics, antiepileptics, atypical antipsychotics, and SSRI/SNRI antidepressants. Among his contributions are his studies on alprazolam, clonazepam, fluoxetine, sertraline, venlafaxine, tryptophan, magnesium, rubidium, risperidone, clozapine, valproate and gabapentin. 

He also specialized in drug-induced disorders, studying tardive dyskinesia and drug-induced movement disorders. He developed a valid and reliable clinical scale, the Extrapyramidal Symtom Rating Scale, to predict and detect the occurrence of drug-induced movement disorders, which is used world-wide in clinical research. He discovered syndromes such rebound anxiety, rebound panic, persistent postwithdrawal disorders and supersensitivity psychosis. Recently, he proposed a new classification of SSRI/SNRI withdrawal.
He has published more than 300 refereed reports in scientific journals, and several book chapters on psychopharmacological treatments and psychiatric semiology. In addition, he has presented more than 600 communications at scientific meetings, lecturing as a guest speaker more than 300 times.

​He sits on the editorial board of the journal Psychotherapy and Psychosomatics. He has been an active Member of the American College of Neuropsychopharmacology (ACNP). He is an Honorary Founding Fellow of the Canadian College of Neuropsychopharmacology. He is Researcher Emeritus, University Mental Health Institute of Montreal, Research Center Fernand Seguin, University of Montreal, Canada
Monica D’Adamo, M.D, Ph.D

Monica D’Adamo, M.D., Ph.D., is Assistant Professor of Internal Medicine in the Department of Systems Medicine of the University of Rome “Tor Vergata” and attending physician at the Internal Medicine and Center for Obesity Unit of Policlinico Tor Vergata. Prof. D’Adamo earned both her degree in Medicine and Surgery and her Board in Endocrinology at the Sapienza University of Rome, and her Ph.D. degree in Molecular Basis of Hormonal Action at the University of Catania. She was member of the Scientific Committee of the Italian Society of Obesity (SIO), and is currently serving as a member of SIO Directive Council. Dr. D’Adamo serves has ad hoc reviewer of several peer review journals.
Her fields of interest range from obesity and diabetes, both clinical and experimental, to clinical osteoporosis.
Bhushan Kapur, DPhil., CChem., FRSC, FACB, FCACB

Dr. Bhushan Kapur graduated with a D.Phil. from the University of Basel, Switzerland in 1967. His doctoral thesis supervisor was Prof. Dr. T. Reichstein, (Nobel Laureate 1956). He was the Director of Laboratories at the Addiction Research Foundation (ARF) from 1971 to May 1995. The toxicology laboratory at ARF was responsible for providing a 24hour/7days emergency identification of drugs including alcohol for almost 80 hospitals in the metropolitan of Toronto.  

From May 1995 to December 2015, he was with the Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children in Toronto. He joined this program as a scientist and a consultant in toxicology after leaving ARF. In June 2000, he was appointed as a consultant and in Laboratory Medicine in the Department of Clinical Pathology, Sunnybrook Health Science Centre and in 2008 a Research Associate in the Sunnybrook Research Institute. From August 2001 to November 2005, he was responsible for the direction of the toxicology laboratory at the St. Michael’s Hospital in Toronto. He was a consultant in toxicology with Canadian Medical Laboratories from 1997 to 2013. 

Dr. Kapur's research interests have been in the biochemical changes in the alcohol and drug using population and pharmacokinetics in the opiate dependent patient.  He has 298 publications and presentations (111 peer reviewed publications and 187 presentations at scientific conferences). Over the years, He has been recipient of grants from various organizations: CIHR, NIH, MRC, NIAA, WHO, Can Found for Fetal Alcohol Research and Alva Foundation Grant in Neonatal and Newborn health.

As a scientist he have developed “Point of Care” devices for Ethanol, Acetaminophen, Salicylate and methanol to be used in the emergency room or clinical laboratory in triaging these poisonings. His other credits include coauthoring a book titled Alcohol and the Identification of Alcoholics, invention and patent of an alcohol dipstick, a computer software program CBAC: Computerized Blood Alcohol Calculator, and book chapters on drugs of abuse.  

Dr. Kapur is Associate Professor in the Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto. He is also Chartered Chemist and Fellow of The Royal Society of Chemistry (UK); Fellow of Academy of Clinical Biochemistry (USA) and Canadian Academy of Clinical Biochemistry (CAN). 

As Inspector for Forensic Urine Drug Testing, American College of Pathologists he has participated in inspections of laboratories requesting certification to do Work Place Drugs of Abuse testing. He has attended ILO (International Labour Organization, UN, Geneva) sponsored Tripartite (Governments, Employers and Labour) meetings in Geneva and Oslo as WHO’s expert in Workplace Drug Testing.
Dr. Irena Nulman, MD, MSc, FRCPC, PhD
Dr. Irena Nulman is a Professor of Pediatrics, Pharmacology, and Pharmacy. She is the Program Director of Fellowship Training in Clinical Pharmacology  at the University of Toronto, Staff Pharmacologist at the Division of Clinical Pharmacology and Toxicology at the Hospital for Sick Children.

She received her medical degree from Ternopol Medical School in Ukraine. She received a Certificate in Neurology in Israel, specializing in Neuropharmacology. She completed her training in Reproductive Toxicology at the Hospital for Sick Children in Toronto. Dr. Nulman joined the faculty in 2004 and received the FRCPC in Neurology in 2008. She is the Director of the Fetal Alcohol Syndrome Clinic at the Hospital for Sick Children. She holds a Diploma in Clinical Epidemiology and a PhD in research methodology from University of Toronto, Canada. 

Dr. Nulman is an Associate Scientist at the Research Institute. She is an expert in behavioural teratology of psychotropic drugs (anticonvulsant, antidepressant, antipsychotic, and alcohol). In collaboration with psychology division she established the Behavioural Teratology Program and actively participated in the development of the Canadian National Guidelines in diagnosing Fetal Alcohol Spectrum Disorder.  
She contributes extensively to behavioral teratology research and is the author of ground-breaking publications in this field.
Tom Leibson, MD
Dr. Tom Leibson is a pediatrician and a senior fellow in the division of clinical pharmacology and toxicology at the hospital for sick children in Toronto, Ontario.

Clinical background includes general pediatric care and exposure to a variety of congenital malformations as well as withdrawal syndromes through extensive work in neonatal special care unit.

​Present clinical activities include counseling regarding drug exposures in pregnancy and developmental follow up of children born to women who abused illicit drugs in pregnancy.

​Research interests include pregnancy outcomes of various in-utero drug exposures and clinical applicability of pharmacokinetics.
Ian James Martins

Dr Ian James Martins presently working at Edith Cowan University, Nedlands, Australia, Centre of Excellence for Alzheimer's Disease Research and Care, Sarich Neuroscience Research Institute. Dr. Ian James Martins is an Editor/Reveiwer for Open Acess Pub/Open Access Journals/MDPI journals and various other international journals. Advisory Board Member for Photon Journal (Portrait 18), Fellow of International Agency for Standards and Ratings (IASR). Conferred with the RICHARD KUHN RESEARCH AWARD-2015 ENDOCRINOLOGY AND METABOLISM. Chief Editor for International Journal of Diabetes Research (2014-2018), Research and Reviews: Neuroscience (2016-2018) and Journal of Diabetes and Clinical Studies (2017-2018). BIT Member (BIT Congress. Inc) with an h-index of 65, (ResearchGate (28) Scopus ID: 7103152779/Mendeley (21), UWA Research Repository (16). Scientist Science Advisory Board (USA), Academic with Academia.edu. Citations accumulated to >4741. Ian James Martins - Semantic Scholar https://www.semanticscholar.org/author/Ian-James-Martins/5258067. ResearchGate Researcher: Ian J Martins | Ph D | Centre of Excellence for Alzheimer's Disease https://www.researchgate.net/profile/Ian_Martins2. ORCID CONNECTING RESEARCHER: Editorial Team www.macrothink.org/journal/index.php/jfs/about/editorialTeamBio/13511 Certificates from Keynote addresses: Biomedicine 2018 (Osaka), Global Experts Meeting on Diabetes, Hypertension, Metabolic Syndrome 2018 (Melbourne), Laboratory Medicine 2018 (Berlin), Immunology World 2018 (Amsterdam), Innovate Pharma 2017 (Sydney), Innovate Neurology 2017, World Diabetes and Endocrinology Summit-2017 (Dubai) and Pharmacology and Ethnopharmacology 2016 (Chicago), AGHC2016 (Kaohsiung). VERIFIED REVEIWER for PUBLONS (50 journals), 98th percentile as assessed for Publons. Organizing Committee Member and Advisory Board Member for 30 conferences around the world (2018-2019). 
Dimitrios A. Vrachatis

Dr. Vrachatis graduated Medical School (National and Kapodistrian University of Athens, Greece) in 2008. He holds an MSc in Health Unit Management (Hellenic Open University, Patras) and a PhD in the field of Biomedical Engineering and Interventional Cardiology (National and Kapodistrian University of Athens, Greece). He has been a scholar of Greek National Scholarship Foundation. In 2019 he completed his Cardiology fellowship in Greek National Health System. He has co-authored more than 70 publications indexed in PubMed (h-index: google scholar 14; scopus 11). He has served as executive editor for Current Pharmaceutical Design journal (published three thematic issues). Dr. Vrachatis has peer-reviewed for 13 international journals (among others: Journal of American Heart Association, Journal of Human Hypertension and Catheterization and Cardiovascular Interventions). He has co-authored 1 international and 8 national medical book chapters.
Martha Maria Pereira

Dr Martha presently working as Director of the WHO Collaborating Center for Leptospirosis Oswaldo Cruz Institute/Oswaldo Cruz Foundation (IOC/FIOCRUZ). Dr Martha’s current research interests focus on Leptospirosis in the broad context and operational concepts of “One Health.” In addition to the academic and research activities there has been direct involvement and participation in national and international efforts as Head of the National Reference Laboratory in Brazil and as Director of the WHO Collaborating Center for Leptospirosis for many years. A Road Map for Leptospirosis Research and Health Policies was developed. It was based on the needs of the countries of Latin America and supported by international experts. The priorities and recommendations were published in 2017 by the Pan American Journal of Public Health. Considering one of the identified priorities, we are now working on the development of a new diagnostic test. It should be affordable to be used by public health laboratories around the world. Detecting and diagnosing the disease at the first clinical presentation is crucial to guide the possible therapeutic alternatives. Leptospirosis severe forms with massive hemorrhage still represent a major challenge in clinical practice.
David Blackburn

Dr. David Blackburn is associate professor of Pharmacy and research chair in Patient Adherence to Drug Therapy at the College of Pharmacy and Nutrition at the University of Saskatchewan. He is also the Director of the Saskatchewan Drug Utilization and Outcomes Research Team (SDUORT).  SDUORT is funded by the Ministry of Health in Saskatchewan to examine provincial drug use issues that are impacted by government policies.  After graduating with a Bachelor of Science in Pharmacy in 1995 from the UofS, he worked briefly as a community pharmacist before completing a hospital residency program in Saskatoon and then moved to Toronto to complete a Doctor of Pharmacy degree from the University of Toronto in 2001.